Congress built the vaccine firewall. Now Congress must defend it.

At the end of 2025, the Advisory Committee on Immunization Practices walked back a cornerstone of American pediatric medicine: the universal hepatitis B birth-dose vaccine. The new recommendation calls for “shared clinical decision-making” for infants of hepatitis B-negative mothers, and no first dose “earlier than 2 months of age.“ The first numbers are now in. On April 27, JAMA Pediatrics published two studies, neither of which was available to the advisory committee when it voted in December. They used different teams and different methods, but they came to identical conclusions. The first modeled a single U. S. birth cohort, made up of 3.6 million infants. Even under perfect adherence, a two-month delay of this vaccine projects 90 additional acute hepatitis B infections, 76 chronic infections, 29 hepatitis B-related deaths, and $16.4 million in lifetime healthcare costs from a single year’s births. And these are best-case numbers. Adherence is never perfect, and the same delay reaches infants whose mothers’ hepatitis B status is unknown. Both gaps drive the toll up. The other study asked what happens when the universal recommendation goes away. History answered this question in 1999, when the American Academy of Pediatrics and the U. S. Public Health Service recommended precisely this kind of delay over concerns about the vaccine. Birth-dose coverage among infants of unscreened mothers collapsed from 53 percent to 7 percent before the policy was reinstated. Apply that historical floor to the December change, and you get 628 additional infant infections per cohort. Roughly 90 percent of perinatally acquired hepatitis B becomes chronic; one in four of those children will die prematurely of cirrhosis or hepatocellular carcinoma. These numbers are conservative; they capture only the direct effect of the policy. The cost the modelers cannot reach is the cascade. Every American newborn nursery delivers three universal interventions in the first hours of life: the hepatitis B vaccine, intramuscular vitamin K, and erythromycin ophthalmic ointment. They are administered together, consented for together, and refused together. When the federal government says one is now optional, the other two come under suspicion by association. The pediatric literature is consistent on this: refuse one, refuse all. Vitamin K deficiency bleeding late form presents at four to eight weeks of life as catastrophic intracranial hemorrhage in a previously well infant. Mortality runs near 20 percent. Survivors are often neurologically devastated. Clusters of this malady have already been reported in the U. S. and Australia in regions with active vaccine skepticism. Ophthalmia neonatorum, untreated, blinds a newborn within days. Erythromycin costs mere pennies, yet refusals are climbing alongside vaccine refusals. The pattern is familiar. In April 2020, a sitting president speculated from a podium about injecting disinfectants. Poison-control calls spiked. After an earlier aside about hydroxychloroquine, an Arizona man died from drinking a chloroquine fish-tank product. In early 2025, the new Health and Human Services secretary recommended vitamin A and cod liver oil during the West Texas measles outbreak. Two unvaccinated children died — the first U. S. measles deaths in a decade. At Covenant Children’s Hospital in Lubbock, physicians documented hypervitaminosis A in measles patients with elevated liver enzymes, after children dosed at home with the secretary’s recommended remedy. He does not retract. He attends a funeral. Now, the next casual sentence: Delay the hepatitis B vaccine by just a few weeks. But the cascade has an upstream source. The Advisory Committee on Immunization Practices, a creation of Congress, is not advisory in the colloquial sense. By statute, its recommendations drive eligibility for the Vaccines for Children program under the Social Security Act and trigger no-cost-sharing coverage requirements under the Affordable Care Act. When the committee weakens a recommendation, federal vaccine financing and private insurance coverage weaken with it. By the time of the December vote, the advisory committee itself had been replaced. In June 2025, the secretary cleared the entire sitting panel and installed new appointees, several with documented histories of vaccine-skepticism. They voted accordingly. The JAMA Pediatrics studies’ results are what that vote produced. The Senate HELP Committee and House Energy and Commerce Committee both have oversight authority here, and both have used it sparingly. Hearings on the composition of the Advisory Committee on Immunization Practices, conflict-of-interest screening, and the evidentiary basis for the December vote are overdue. So is legislation insulating committee members from secretarial dismissal without cause. Inspector general protections were supposed to do that work but failed. I have been an attending intensive care unit physician at UCLA for more than 40 years. I watched science survive bad presidents and bad administrators. But it will not survive a captured advisory committee without a fight from the branch that built it. The Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices were supposed to be the firewall. They have become talking points. Tonight, a parent will look down at her newborn and say, “Let’s wait.” But the virus will not wait, and neither will the bleed. Robert B. Shpiner, MD, FCCP, FAASM, is a clinical professor of medicine (pulmonary and critical care) and associate professor of neurosurgery at the David Geffen School of Medicine at UCLA, where he has practiced in the Neurocritical Care Unit at Ronald Reagan UCLA Medical Center for over 40 years. Copyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.